THERANOSTIC ANTIBODY-DRUG CONJUGATES: NEW FRONTIERS IN DIAGNOSIS AND TREATMENT OF CANCER

THERANOSTIC ANTIBODY-DRUG CONJUGATES: NEW FRONTIERS IN DIAGNOSIS AND TREATMENT OF CANCER

Authors

Abstract

Antibody-drug conjugates (ADCs) are molecular systems that unlike classic chemotherapy hold the potential to change the nature of cancer treatment. ADCs combine both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient eradication of cancer cells.  Yet, the visualization of drug release event in "life" by fluorescence monitoring is emerging methodology and can provide a vital info about pharmacokinetics of ADCs. Fluorescent dyes linked to ADCs create theranostic (therapeutic and diagnostic) modalities that afford such a real-time info on the efficacy of drug delivery including quantitative monitoring of drug distribution. To achieve this goal, we equipped an ADCs with a turn-on near-infrared (NIR) dye, sensitive to drug release, and a reference NIR dye. The results suggest that our ratiometric design could be successfully employed for quantitative monitoring of drug release degree and the proposed method is unaffected by the experimental variation, as well as the variation in the mouse response to the administrated conjugate. The future aspects and insights of theranostic ADCs with improving therapeutic index will be discussed.

Downloads

Download data is not yet available.

Author Biography

Gary Gellerman, Ariel University

Full Professor, Department of Chemical Sciences

References

T. Etrych et al. "Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas". Cancers 2022, 14, 626.

E. Thankarajan et al. "Antibody guided activatable NIR photosensitizing system for fluorescently monitored photodynamic therapy with reduced side effects" Journal of Controlled Release 2022, 343, 506–517.

E. Thankarajan et al. ''Antibody-guided, dual NIR dye ratiometric drug delivery system for quantification of drug release in-vivo'' ACS Analytical Chemistry 2021, 93, 23, 8265-8272.

D. Poplinger et al. "Ratiometric fluorescence monitoring of antibody-guided drug delivery to cancer cells" Bioconjugate Chemistry 2021, 32, 8, 1641–1651.

L. Patsenker and G. Gellerman, “Fluorescent Reporters for Drug Delivery Monitoring” Israel Journal of Chemistry 2020, 60, 1 – 16.

Published

2022-10-01

Issue

Section

Plenary lectures
Loading...